Pressmeddelande -
DEVERSIFY HAS CARRIED OUT A RIGHTS ISSUE, RAISING PROCEEDS OF SEK 11,2 MILLION
Deversify AB has successfully completed a rights issue raising proceeds of SEK 11,2 million. The rights issue has primarily been subscribed for by new Swedish investors from all over the country. Net cash from the rights issue will be used for the continual building and strengthening of the organisation and to support the company’s commercial strategy.
”This rights issue is our largest by far and allows us to step into the next phase of business development and enterprise-building”, says Anders Murman, CEO. He continues: ”With our device, Acetrack, you can measure your rate of fat burning in real time. We are now focusing on accelerating the expansion of Acetrack in Europe and launching our updated, next generation, software. We will also be launching new projects on microsensors and new research on health data – everything to improve the understanding of individual metabolism”.
About Deversify:
Deversify is a Swedish R&D company offering tech solutions in consumer health. We develop and commercialize mobile electronic devices and apps to monitor biomarkers for individualized health. Our products help people understand — and improve — their own health. Our mission is to act as a good force against today’s lifestyle diseases – such as obesity, diabetes, addictions, and cardiovascular disease. Deversify operates in growing consumer health markets which today in Europe and US alone are valued at over USD 5 billion. Our first product, the ketone breathalyzer Acetrack®️, measures if your body is burning fat and is currently sold to health-tech consumers. Deversify is here to help you understand your wellbeing holistically – inside and out, from ketones to ECG.
Contact:
Anders Murman, CEO
anders.murman@deversify.com
+46 70 546 50 62
deversify.com
getacetrack.com.
Relaterade länkar
Ämnen
- Ekonomi, finans
Kategorier
- finansiering
- deversify
- keto
- financing
- medtech
- mobile-health
- e-hälsa
- ipo
- mobilhälsa
- startup
Om Deversify:
Deversify är ett svenskt R&D-företag som erbjuder tekniska lösningar inom området konsumenthälsa. Vi utvecklar och kommersialiserar mobila, elektroniska enheter och appar för mätning av biomarkörer för individuell hälsostatus. Våra produkter hjälper människor att förstå – och att förbättra – sin egen hälsa. Vårt uppdrag är att verka som en god motkraft mot dagens livsstilssjukdomar såsom övervikt, diabetes, beroendesjukdomar och hjärt- och kärlsjukdomar. Deversify fokuserar på växande konsumentmarknader som idag inom hälsoområdet värderas till över 50 miljarder SEK enbart i Europa och USA. Vår flaggskeppsprodukt, utandningsmätaren Acetrack®️, mäter om din kropp är i fettförbränningsläge och säljs till health tech-användare. Deversify är här för att hjälpa dig förstå din egen hälsa holistiskt – inifrån och ut – från ketoner till EKG.
About Deversify:
Deversify is a Swedish R&D company offering tech solutions in consumer health. We develop and commercialize mobile electronic devices and apps to monitor biomarkers for individualized health. Our products help people understand — and improve — their own health. Our mission is to act as a good force against today’s lifestyle diseases – such as obesity, diabetes, addictions, and cardiovascular disease. Deversify operates in growing consumer health markets which today in Europe and US alone are valued at over USD 5 billion. Our first product, the ketone breathalyzer Acetrack®️, measures if your body is burning fat and is currently sold to health-tech consumers. Deversify is here to help you understand your wellbeing holistically – inside and out, from ketones to ECG.
